Technological Innovations to Speed Protein Characterization
Over the last two decades, more than one hundred mAbs have been approved or are in regulatory review in the US and EU. This growth has led to an increasing need for developing rapid technologies to support the characterization of mAbs to secure drug product safety, quality, and efficacy.
In this presentation we present several mass spectrometry-based technologies used in a stage appropriate manner to dramatically shorten timelines and improve throughput in biologics research. Examples include; automated and rapid sample preparation, multiplexed workflows, high-resolution SLIM-IMS-MS, RapidFire-MS, and our labs ongoing efforts for an end-to-end automated process from sample preparation to reporting.
For Research Use Only. Not for use in diagnostic procedures.
Presenter: Harsha Gunawardena, PhD (Janssen Research & Development, Johnson & Johnson)
Harsha Gunawardena obtained his Ph.D. in Analytical Chemistry from Purdue University and a Master of Science degree in Analytical Chemistry from University of North Carolina. He was a post-doctoral fellow at the Lineberger comprehensive cancer center, UNC school of medicine where his research focused on refining quantitative platforms for large-scale clinical proteomics and proteogenomic analysis. He was a co-investigator for the NCI clinical proteomics tumor analysis consortium (CPTAC), the ENCODE consortium. His industry career as scientist started at Bayer Health Care providing mass spectrometry and bioanalytical support of plasma-based therapeutics. He later worked at Amgen applying proteomics methods to support biomarker programs and discovery programs in oncology and inflammation. In his current role at Janssen R&D, Johnson & Johnson, he supports discovery early development programs that span several therapeutic modalities.
